1. GPCR/G Protein
  2. Cannabinoid Receptor

WIN 55,212-2 Mesylate (Synonyms: (R)-(+)-WIN 55212)

Cat. No.: HY-13291 Purity: 98.98%
Handling Instructions

WIN 55,212-2 (Mesylate) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Kis of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.

For research use only. We do not sell to patients.
WIN 55,212-2 Mesylate Chemical Structure

WIN 55,212-2 Mesylate Chemical Structure

CAS No. : 131543-23-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 69 In-stock
5 mg USD 60 In-stock
10 mg USD 84 In-stock
50 mg USD 312 In-stock
100 mg USD 552 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    WIN 55,212-2 Mesylate purchased from MCE. Usage Cited in: Front Mol Neurosci. 2017 Aug 7;10:247.

    Bar graphs show levels of GABAAR-α2 mRNA and GABAAR-α2 protein in BLA of control mice treated with BLA-injection of H89 or GF109203X (GFX); in MPTP-mice treated with BLA-injection of PMA, or the co-administration of quinpirole and H89 (quin/+H89) or GF109203X (quin/+GFX).
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    WIN 55,212-2 (Mesylate) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Kis of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.

    IC50 & Target

    Ki: 62.3 nM (human recombinant CB1), 3.3 nM (human recombinant CB2)

    In Vitro

    WIN 55,212-2 is more potent in CHO-CB2 cells than in CHO-CB1 cells by a factor of 6O. WIN 55,212-2 has no effect on arachidonic acid release in CHO-CB2 or control CHO cells. WIN 55,212-2 fails to stimulate any increase in intracellular Ca2+ up to 10 μM[1]. In primary cultures of rat cerebral cortex neurons, WIN 55,212-2 (0.01--100 nM) increases extracellular glutamate levels, displaying a bell-shaped concentration-response curve. The facilitatory effect of WIN 55,212-2 (1 nM) is fully counteracted by SR141716A (10 nM), by the replacement of the normal Krebs Ringer-bicarbonate buffer with a low Ca2+ medium (0.2 mM) and by the IP(3) receptor antagonist xestospongin C (1 μM)[2]. WIN 55,212-2 evokes CGRP release from TG neurons in vitro (EC50=26 μM) in a concentration- and calcium-dependent manner. WIN 55,212-2-2 neither inhibits capsaicin-evokes CGRP release nor does it inhibit forskolin-, isoproteranol- or prostaglandin E2-stimulated cAMP accumulation. WIN 55,212-2 significantly inhibits (EC50=1.7 μM) 50 mm K+-evoked CGRP release by approximately 70%. WIN 55,212-2 inhibition of 50 mm K+-evoked CGRP release is not reversed by antagonists of cannabinoid type 1 (CB1) receptor, but is mimicks in magnitude and potency (EC50=2.7 μM) by its cannabinoid-inactive enantiomer WIN 55,212-2-3[3].

    In Vivo

    In the prefrontal cortex WIN 55,212-2 (0.1 and 1 mg/kg i.p.) increases dialysate glutamate levels from of the awake rat, while the lower (0.01 mg/kg) and the higher (2 mg/kg) doses are ineffective. Furthermore, the WIN 55,212-2 (0.1 mg/kg)- induced increase of dialysate glutamate levels is counteracted by pretreatment with the selective CB(1) receptor antagonist SR141716A (0.1 mg/kg, i.p.) and by the local perfusion with a low-calcium Ringer solution (Ca2+ 0.2 mM)[2]. WIN 55,212-2 (0.5, 1, 3, 5, 10 and 15 mg/kg, i.p.) does not alter the seizure threshold at low doses, while higher doses of the drug significantly increases the threshold in a dose-dependent manner. The anticonvulsant effect of WIN 55,212-2, which is observed with doses as high as 5 mg/kg, can be observed with doses as low as 0.5 mg/kg in groups pre-treated with 20 mg/kg of pioglitazone[4].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.9135 mL 9.5674 mL 19.1347 mL
    5 mM 0.3827 mL 1.9135 mL 3.8269 mL
    10 mM 0.1913 mL 0.9567 mL 1.9135 mL
    Please refer to the solubility information to select the appropriate solvent.
    Animal Administration

    WIN 55,212-2 is formulated in 1% aqueous solution of DMSO.

    In experiment 1, different doses of WIN 55,212-2 (0.5, 1, 3, 5, 10 and 15 mg/kg) are injected 60 min prior to the determination of clonic seizure threshold induced by intravenous administration of PTZ solution. Control animals receive the same volume of the vehicle (1% aqueous solution of DMSO). The doses and time point are chosen on the basis of pilot studies. In experiment 2, in order to confirm the anticonvulsant effects of pioglitazone, different doses (10, 20, 40 and 80 mg/kg) are administered 4 h prior to PTZ in distinct groups of mice. The corresponding control groupreceive the appropriate vehicle (CMC 1%) at the same time point. In experiment 3, The additive anti epileptic effects of WIN 55,212-2 and pioglitazone are examined; mice receive acute administration of pioglitazone (10 or 20 mg/kg) 3 h before WIN 55,212-2 (0.5 or 1 mg/kg) and 4 h before PTZ. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.



    O=C(C1=C2C=CC=CC2=CC=C1)C3=C(N4[[email protected]@H](COC5=C4C3=CC=C5)CN6CCOCC6)C.CS(=O)(O)=O

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 34 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 98.98%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    WIN 55,212-2 Mesylate
    Cat. No.: